Bionexus Gene Lab CORP DEF 14A proxy statements

BioNexus Gene Lab Corp. announces its 2025 Annual Meeting of Stockholders to vote on director re-elections, a new equity incentive plan, and auditor re-appointment.

BioNexus Gene Lab Corp. is holding a special meeting to seek stockholder approval for a reverse stock split to meet Nasdaq's minimum bid price requirement and gain flexibility for future capital raising.

BioNexus Gene Lab Corp. is asking stockholders to approve a reverse stock split to meet Nasdaq's minimum bid price requirement and gain flexibility for future capital raising.

BioNexus Gene Lab Corp. is holding its annual meeting on October 4, 2024, to vote on key proposals including the election of directors, a reverse stock split, and a new stock incentive plan.

BioNexus Gene Lab Corp. announces the removal of eight directors and the election of three new directors via written consent from stockholders holding approximately 50.1% of voting securities.